Investor focus is turning to Cencora (formerly AmerisourceBergen) as it prepares to release its quarterly figures. The healthcare logistics giant has garnered significant positive attention following a major analyst upgrade, setting a confident tone for its upcoming earnings announcement scheduled for Wednesday, February 4.
Major Firm Raises Rating and Price Target
In a notable move on Thursday, investment bank Morgan Stanley revised its stance on Cencora. The firm upgraded the stock from “Equal Weight” to “Overweight,” signaling increased confidence in its prospects. Concurrently, Morgan Stanley’s analysts lifted their price target substantially from $361 to $400 per share.
This optimistic reassessment is attributed to Cencora’s strategic expansion within the high-margin specialty pharmaceuticals sector. A key development cited is the company’s acquisition of a majority stake in OneOncology, a move that significantly bolsters its footprint in specialized oncology practice networks. The upgrade reflects broader analyst confidence in the company’s ongoing portfolio optimization efforts.
Sector Strength and Peer Endorsement
The upgrade aligns with a period of robust fundamental performance observed across the healthcare logistics industry, driven by strong cash flows and a strategic shift toward more profitable business segments. This positive sentiment is not isolated; just one week prior, analysts at Jefferies reaffirmed a “Buy” rating on Cencora, commending its consistent operational execution.
Should investors sell immediately? Or is it worth buying AmerisourceBergen?
The market environment for healthcare distribution remains resilient as 2026 begins. While excitement around specific drug classes like GLP-1 agonists may moderate, underlying pharmaceutical volumes are expected to stay stable. Institutional investors are particularly noting the growing importance of specialized therapies, an area where Cencora is actively expanding.
Earnings Expectations and Strategic Moves
All eyes are now on the quarterly report due before the U.S. market opens on February 4. The current Wall Street consensus projects earnings per share of $4.05, which would represent an 8.6% increase compared to the same period last year. Revenue is anticipated to rise by approximately 5.5% to around $85.97 billion.
Beyond the headline numbers, market participants will scrutinize the company’s capital allocation strategy. Recent initiatives include the repurchase of shares from Walgreens Boots Alliance and the ongoing integration of new acquisitions, such as Retina Consultants of America. These actions underscore management’s focus on shaping its business mix for enhanced profitability.
The accompanying conference call, scheduled for 14:30 CET, is expected to provide clarity on the contribution of new specialty segments to overall performance and whether the company’s full-year guidance will be adjusted following its recent strategic purchases.
Ad
AmerisourceBergen Stock: Buy or Sell?! New AmerisourceBergen Analysis from January 31 delivers the answer:
The latest AmerisourceBergen figures speak for themselves: Urgent action needed for AmerisourceBergen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 31.
AmerisourceBergen: Buy or sell? Read more here...
